Medical Advocates
Kaposi’s Sarcoma
  Drugs
General Reports 
 Daunorubicin
Docetaxel
Doxorubicin
Imatinib
 Imiquimod
Interferon
 Interleukins
 Irinotecan
Nicotine

  		Paclitaxel
Rapimycin
 Sirolimus
Thalidomide
Toremifene  
Vinblastine
Topical Treatments
Antiretrovirals



 
KS Management Main New/Newsworthy Home Page
Last Update:  July 02, 2008
Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader
General Reports
         

          Journal Papers, Abstracts, and Commentaries

 
Investigational agents for treatment of AIDS-related Kaposi’s sarcoma.
Konstantinopoulos PA, Sullivan RJ, Karamouzis MV, Dezube BJ.
Expert Opin Investig Drugs. 2007 Apr;16(4):495-504.
 Abstract
 
Timing of highly active antiretroviral therapy and chemotherapy for Kaposi’s sarcoma in
patients with HIV infection.
Loke WC, Spittle MF, Mitchell S, Kulasegaram R. 
Int J STD AIDS. 2006 Aug;17(8):565-6.
Abstract
 
Treatments of AIDS-related Kaposi’s sarcoma.
Aversa SM, Cattelan AM, Salvagno L, et al
Crit Rev Oncol Hematol. 2005 Mar;53(3):253-65..
 Abstract
 
Novel pharmacological therapies for the treatment of AIDS-related Kaposi’s
sarcoma.
Cattelan AM, Trevenzoli M, Aversa SM.
Expert Opin Investig Drugs. 2004 May;13(5):501-513.
 Abstract

Therapy of AIDS-associated Kaposi’s sarcoma: targeting pathogenetic
mechanisms.
Krown SE.
Hematol Oncol Clin North Am. 2003 Jun;17(3):763-83.
Abstract
 
          Conference Reports, Abstracts, and Posters
 
  Incidences Trends of Kaposi’s Sarcoma in the HAART Era and Comparison
of Different HAART Regimens. Results from the French Hospital Database
on HIV
S Grabar, B Abraham, A Mahamat, et al
(12 CROI)
 Abstract
Daunorubicin
         
          Journal Papers, Abstracts, and Commentaries
 
  Liposomal daunorubicin as treatment for Kaposi’s sarcoma.
Petre CE, Dittmer DP.   
Int J Nanomedicine. 2007;2(3):277-88.
Abstract
Docetaxel
         

          Journal Papers, Abstracts, and Commentaries

 
Docetaxel in anthracycline-pretreated AIDS-related Kaposi’s sarcoma: a retrospective study.
Autier J, Picard-Dahan C, Marinho E, et al 
Br J Dermatol. 2005 May;152(5):1026-9
 Abstract
 
Weekly docetaxel is safe and effective in the treatment of advanced-stage acquired
immunodeficiency syndrome-related Kaposi sarcoma.
Lim ST, Tupule A, Espina BM, Levine AM.
Cancer. 2004 Dec 1;
 Abstract
Doxorubicin
         
          Journal Papers, Abstracts, and Commentaries
 
 
Long-Term Prognosis of HIV-Infected Patients with Kaposi Sarcoma Treated with Pegylated
Liposomal Doxorubicin.
Martín-Carbonero L, Palacios R, Valencia E, et al
Clin Infect Dis. 2008 Jun 26.
 Abstract
 
Pegylated liposomal doxorubicin in the treatment of AIDS-related Kaposi’s sarcoma.
Udhrain A, Skubitz KM, Northfelt DW.
Int J Nanomedicine. 2007;2(3):345-52.
 Abstract
 
Binding and internalization of NGR-peptide-targeted liposomal doxorubicin (TVT-DOX) in
CD13-expressing cells and its antitumor effects.
Garde SV, Forté AJ, Ge M, et al 
Anticancer Drugs. 2007 Nov;18(10):1189-200.
Abstract
 
Phase II study of pegylated liposomal doxorubicin in combination with interleukin-12 for
AIDS-related Kaposi’s sarcoma.
Little RF, Aleman K, Kumar P, et al
Blood. 2007 Sep 10;
Abstract

A WEEK-IN-REVIEW FEATURED REPORT
FULL TEXT ARTICLE
 A Randomized, Double-Blind Study of Pegylated Liposomal Doxorubicin for the Treatment of
AIDS-Related Kaposi’s Sarcoma.
Cooley T, Henry D, Tonda M, Sun S,
 Oncologist. 2007 Jan;12(1):114-23.
Paper

Disseminated classic Kaposi’s sarcoma. Two cases with excellent response to pegylated
liposomal doxorubicin.
Castiñeiras I, Almagro M, Rodríguez-Lozano J, et al
J Dermatolog Treat. 2006;17(6):377-80.
 Abstract
 
Role of pegylated lyposomal doxorubicin (PLD) in systemic Kaposi’s sarcoma: a systematic
review.
Di Trolio R, Di Lorenzo G, Delfino M, De Placido S.
Int J Immunopathol Pharmacol. 2006 Apr-Jun;19(2):253-63.
 Abstract
 
Treatment of HIV-1-associated Kaposi’s sarcoma with pegylated liposomal doxorubicin and
HAART simultaneously induces effective tumor remission and CD4+ T cell recovery.
Lichterfeld M, Qurishi N, Hoffmann C, et al
Infection. 2005 Jun;33(3):140-7.
Abstract
 
Pharmacokinetics of pegylated liposomal Doxorubicin : review of animal and
human studies.
Gabizon A, Shmeeda H, Barenholz Y.
Clin Pharmacokinet 2003;42(5):419-36
 Abstract
 
Response to liposomal doxorubicin and clinical outcome of HIV-1-infected patients
with Kaposi’s sarcoma receiving highly active antiretroviral therapy.
Nunez M, Saballs P, Valencia ME, et al.
HIV Clin Trials 2001 Sep-Oct;2(5):429-37
 Abstract
 
         Conference Reports, Abstracts, and Posters
 
 
Long-term prognosis of HIV positive patients with kaposi sarcoma treated with pegylated
liposomal doxorubicin
Martin Carbonero L., Palacios R., Valencia M.E., et al
(XVI  International AIDS Conference)
 Abstract
 
 
Treatment of Kaposi’s Sarcoma with Liposomal Daunorrubicin (daunoxome) is
associatedwith less side effects and similar efficacy compared to other treatment options
J Madruga, F Araujo, ACA Bandeira, et al
 (11 CROI)
 Abstract
 
Pegylated Liposomal Doxorubicin plus HAART vs HAART alone in HIV Patients with
Kaposi´s Sarcoma. A Spanish Multicenter, Randomized Prospective Study
 L Martin-Carbonero, A Barrios, P Saballs, et al 
(11 CROI)
 Abstract
 
Imatinib
         

          Journal Papers, Abstracts, and Commentaries

 
Imatinib interferes with survival of multi drug resistant Kaposi’s sarcoma cells.
Basciani S, Vona R, Matarrese P, et al  
FEBS Lett. 2007 Dec 22;581(30):5897-903.
 Abstract
 
Imatinib-Induced Regression of AIDS-Related Kaposi’s Sarcoma.
Koon HB, Bubley GJ, Pantanowitz L, et al
J Clin Oncol. 2004 Nov 30;
 Abstract
Imiquimod
         

          Journal Papers, Abstracts, and Commentaries

 
Imiquimod 5% cream for treatment of HIV-negative Kaposi’s sarcoma skin lesions:
 A phase I to II,open-label trial in 17 patients.
Célestin Schartz NE, Chevret S, Paz C, et al
 J   Am Acad Dermatol. 2007 Dec 6
Abstract
 
Development of Kaposi’s sarcoma under sirolimus-based immunosuppression and
successful treatment with imiquimod.
Babel N, Eibl N, Ulrich C, et al  Transpl Infect Dis. 2007 Apr 11;
Abstract
Interferon
         

          Journal Papers, Abstracts, and Commentaries
 
 
Treatment of AIDS-related Kaposi’s sarcoma with interleukin-12: rationale and preliminary
evidence of clinical activity.
Yarchoan R, Pluda JM, Wyvill KM, et al 
Crit Rev Immunol. 2007;27(5):401-14.
 Abstract
 
AIDS-associated Kaposi’s sarcoma: Is there still a role for interferon alfa?
Krown SE. 
Cytokine Growth Factor Rev. 2007 Jul 24;
 Abstract
 
Interferon-alpha2b With Protease Inhibitor-Based Antiretroviral Therapy in Patients With
AIDS-Associated Kaposi Sarcoma: An AIDS Malignancy Consortium Phase I Trial.
Krown SE, Lee JY, Lin L, et al  
J Acquir Immune Defic Syndr. 2006 Feb 1;41(2):149-153.
 Abstract

Management of Kaposi sarcoma: the role of interferon and thalidomide.
 Krown SE.
 Curr Opin Oncol 2001 Sep;13(5):374-81
 Abstract
Irinotecan
         

          Journal Papers, Abstracts, and Commentaries

 
Evidence of activity of Irinotecan in patients with advanced AIDS-related
Kaposi’s sarcoma.
Vaccher E, di Gennaro G, Simonelli C, et al 
AIDS. 2005 Nov 4;19(16):1915-6.
Abstract
Interleukins
         

IL-12

          Journal Papers, Abstracts, and Commentaries

 
Activity of subcutaneous interleukin-12 in AIDS-related Kaposi’s sarcoma.
Little RF, Pluda JM, Wyvill KM
 Blood. 2006 Feb 28;
 Abstract
Nicotine
 

          Journal Papers, Abstracts, and Commentaries

  Treatment of classic Kaposi sarcoma with a nicotine dermal patch: a phase II clinical trial.
Goedert JJ, Scoppio BM, Pfeiffer R, et al
 J Eur Acad Dermatol Venereol. 2008 Apr 1
 Abstract
Paclitaxel
 

          Journal Papers, Abstracts, and Commentaries

 
Paclitaxel Induces Apoptosis in AIDS-Related Kaposi’s Sarcoma Cells.
Cai J, Zheng T, Masood R, et al 
Sarcoma. 2000;4(1-2):37-45.
 Abstract
 
Weekly paclitaxel for advanced aggressive classic Kaposi sarcoma:
experience in 17 cases.
Brambilla L, Romanelli A, Bellinvia M, et al
Br J Dermatol. 2008 Mar 20
Abstract
 

Potential drug interaction with paclitaxel and highly active antiretroviral therapy
in two patients with AIDS-associated Kaposi sarcoma.
Bundow D, Aboulafia DM.
Am J Clin Oncol. 2004 Feb;27(1):81-4.
 Abstract
Rapamycin
 

          Journal Papers, Abstracts, and Commentaries

  Monitoring antitumor efficacy of rapamycin in Kaposi sarcoma.
Di Paolo S, Teutonico A, Ranieri E, et al 
Am J Kidney Dis. 2007 Mar;49(3):462-70.
 Abstract
Sirolimus
 

          Journal Papers, Abstracts, and Commentaries

 
Kaposi’s sarcoma resolves after sirolimus therapy in a patient with pemphigus vulgaris.
Saggar S, Zeichner JA, Brown TT, et al  
Arch Dermatol. 2008 May;144(5):654-7.
 Abstract

Sirolimus for visceral and cutaneous Kaposi’s sarcoma in a renal-transplant recipient.
Gheith O, Bakr A, Wafa E, et al
Clin Exp Nephrol. 2007 Sep;11(3):251-4.
Abstract
Thalidomide
 

          Journal Papers, Abstracts, and Commentaries

  Management of Kaposi sarcoma: the role of interferon and thalidomide.
 Krown SE.
 Curr Opin Oncol 2001 Sep;13(5):374-81
 Abstract
   
  Clinical aspects and management of AIDS-related Kaposi’s sarcoma.
 Levine AM, Tulpule A.
 Eur J Cancer 2001 Jul;37(10):1288-95
 Abstract
   
  Activity of thalidomide in AIDS-related Kaposi’s sarcoma.
 Little RF, Wyvill KM, Pluda JM, et al.
 J Clin Oncol 2000 Jul;18(13):2593-602
 Abstract
Toremifene
 

         Journal Papers, Abstracts, and Commentaries

  Antiproliferative Properties of Toremifene on AIDS-Related Kaposi’s Sarcoma
Cells.
Hong A, Leigh BR.  
Chemotherapy 2002 Dec;48(5):238-243
 Abstract		  
Vinblastine
 

          Journal Papers, Abstracts, and Commentaries

  Chemotherapy of disseminated cutaneous classic Kaposi’s sarcoma with
vinblastine.
Turk HM, Buyukberber S, Canci C, et al.
J Dermatol 2002 Oct;29(10):657-60
 Abstract		  
Topical Treatments
 
          Journal Papers, Abstracts, and Commentaries
 
 

Antitumor activity of oral 9-cis-retinoic acid in HIV-associated Kaposi’s sarcoma.
Miles SA, Dezube BJ, Lee JY, et al. 
AIDS 2002 Feb 15;16(3):421-429
 Abstract

Phase III vehicle-controlled, multi-centered study of topical alitretinoin gel  0.1% in
cutaneous AIDS-related Kaposi’s sarcoma.
Bodsworth NJ, Bloch M, Bower M, et al.
Am J Clin Dermatol 2001;2(2):77-87
 Abstract

  

KS Management Main New/Newsworthy Home Page

 Kaposi’s Sarcoma Drugs